1. Phylogeny  
   MAPK14, commonly referred to as p38α, is a member of the p38 mitogen‐activated protein kinase (MAPK) family, which comprises four isoforms (p38α, p38β, p38γ, and p38δ) present in higher eukaryotes. p38α is the most extensively studied and is ubiquitously expressed in mammalian tissues. It is evolutionarily conserved from yeast to man, representing the ortholog of the yeast Hog1 kinase that is activated in response to hyperosmotic stress. This conservation is reflected in the shared architecture and activation mechanisms between p38α and its yeast counterpart. Within the broader kinome, p38α is classified under the stress‐activated MAPK group, and its molecular lineage can be traced back to the common ancestor of eukaryotes alongside other MAP kinases involved in stress and immune signaling (cargnello2011activationandfunction pages 4-5, cuenda2007p38mapkinasespathway pages 1-2, martinblanco2000p38mapksignalling pages 1-2).
2. Reaction Catalyzed  
   MAPK14 catalyzes the transfer of the γ‐phosphate group from ATP to hydroxyl groups on serine and/or threonine residues of substrate proteins. The general chemical reaction can be represented as: ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺. This phosphorylation event is central to the propagation of intracellular signaling, as the addition of a phosphate moiety triggers conformational changes in substrates that affect their activity, interactions, and cellular localization (cuenda2007p38mapkinasespathway pages 1-2, kyriakis2012mammalianmapksignal pages 3-5).
3. Cofactor Requirements  
   The catalytic activity of MAPK14 is dependent on the presence of divalent metal ion cofactors, most notably Mg²⁺, which is required for the proper binding and orientation of ATP in the active site. In some in vitro scenarios, Mn²⁺ may substitute for Mg²⁺ to support kinase activity, although Mg²⁺ is generally considered the physiological cofactor in cells. This requirement ensures proper positioning of ATP for the subsequent phosphoryl transfer reaction (cuenda2007p38mapkinasespathway pages 1-2, lin2007novelstrategiesfor pages 1-2).
4. Substrate Specificity  
   MAPK14 exhibits broad substrate specificity and phosphorylates an extensive array of proteins, with estimates ranging from approximately 200 to 300 distinct substrates. The kinase displays a preference for serine/threonine residues that are followed by a proline, constituting a minimal consensus motif denoted as S/T-P. In addition to the minimal motif, substrate recognition by p38α is frequently enhanced by specific docking domains and sequences—such as D domains and DEF motifs—that facilitate stable and selective interactions between the kinase and its substrates. Examples of well‐characterized substrates include downstream kinases like MAPK-activated protein kinase-2 (MK2), transcription factors including ATF1/2/6 and MEF2 family members, and proteins involved in chromatin remodeling. This broad specificity is a key factor enabling p38α to integrate and coordinate diverse cellular responses, especially under stress and inflammatory conditions (cargnello2011activationandfunction pages 4-5, cuenda2007p38mapkinasespathway pages 1-2, yong2009thep38mapk pages 1-2).
5. Structure  
   The three-dimensional organization of MAPK14 is typical of classical serine/threonine protein kinases, and its overall architecture is divided into a smaller N-terminal lobe and a larger C-terminal lobe that together form a catalytic cleft. The enzyme harbors a central kinase domain that includes several key structural features:  
   • The N-terminal lobe is primarily composed of β-sheets and a conserved C-helix, which plays an important role in ATP binding and positioning.  
   • The C-terminal lobe is predominantly α-helical and contains the activation loop, which encompasses the conserved Thr-Gly-Tyr (TGY) motif essential for kinase activation. Dual phosphorylation of this motif triggers a conformational change that aligns the catalytic residues and activates the kinase.  
   • A unique nuclear translocation sequence is present within the kinase insert domain, facilitating the import of p38α into the nucleus upon activation.  
   • Structural studies and crystallographic analyses reveal the presence of an ATP binding pocket defined by a set of conserved residues, including those that participate in the formation of a hydrophobic spine and contribute to the enzyme’s catalytic efficiency. These features enable selective binding of ATP-competitive inhibitors, such as the pyridinyl imidazole class (SB203580, SB202190) and the allosteric inhibitor BIRB0796 (cargnello2011activationandfunction pages 4-5, cuenda2007p38mapkinasespathway pages 12-13, cuadrado2010mechanismsandfunctions pages 1-1, ono2000thep38signal pages 1-2).
6. Regulation  
   MAPK14 is tightly regulated through multiple mechanisms to ensure precise control over its activity in response to extracellular and intracellular stimuli. The primary regulatory mechanism involves the dual phosphorylation of the TGY motif within the activation loop by upstream dual-specificity MAP kinase kinases (MAP2Ks), particularly MKK3 and MKK6. This phosphorylation is essential for the full catalytic activation of p38α. In addition to the canonical MAP2K-mediated activation, non-canonical pathways exist:  
   • In T lymphocytes, p38α can be activated by tyrosine phosphorylation at residue Y323, leading to subsequent autophosphorylation—this mechanism is particularly relevant during T-cell receptor signaling.  
   • The adaptor protein TAB1 (TAK1-binding protein 1) can directly interact with and induce autophosphorylation of p38α, contributing to its activation independently of MAP2Ks.  
   Beyond phosphorylation, p38α activity is subject to negative regulation by protein phosphatases, including various MAP kinase phosphatases (MKPs), which dephosphorylate its activation loop, thereby attenuating the signal. Additionally, conformational regulation and interactions with scaffold proteins help localize p38α to specific subcellular compartments and promote selective substrate phosphorylation. Such spatial organization ensures responsiveness to diverse stimuli such as oxidative stress, ultraviolet irradiation, hypoxia, and pro-inflammatory cytokines (cuenda2007p38mapkinasespathway pages 12-13, lin2007novelstrategiesfor pages 5-6, marber2011thep38mitogenactivated pages 1-2, schindler2007p38pathwaykinases pages 2-4).
7. Function  
   MAPK14 plays a central role in mediating cellular responses to a variety of stress stimuli and pro-inflammatory signals. As a serine/threonine kinase, it modulates the activity of numerous downstream targets, thereby orchestrating a wide spectrum of biological processes.  
   In the cytoplasm, p38α regulates several critical functions such as:  
   • Inflammatory responses by controlling the transcription and stability of cytokine mRNAs. It phosphorylates substrates like MK2 and MK3, which in turn regulate the post-transcriptional processing of inflammatory mediators including TNF-α, IL-6, and IL-8.  
   • Protein turnover and receptor internalization through phosphorylation of proteins involved in endocytic pathways and the regulation of ubiquitin ligase activity. For instance, p38α phosphorylates the ubiquitin ligase SIAH2, thereby modulating its activity toward substrates such as EGLN3, and it phosphorylates components of clathrin-mediated endocytosis involved in EGFR internalization.  
   In the nucleus, p38α phosphorylates a range of transcription factors—such as ATF1, ATF2, ATF6, ELK1, and p53—leading to alterations in gene expression that are critical for stress-induced gene activation, cell cycle arrest, differentiation, and apoptosis. Furthermore, p38α modulates chromatin accessibility by phosphorylating histones and chromatin remodelers, which facilitates the recruitment of the transcription machinery to promoters of immediate-early genes, a process that is particularly important for the inflammatory response.  
   Expressed ubiquitously, MAPK14 is hence involved in numerous physiological and stress-induced processes, including the regulation of immune responses, cell survival, and the maintenance of cellular homeostasis under conditions of injury or environmental stress (cargnello2011activationandfunction pages 4-5, cuenda2007p38mapkinasespathway pages 1-2, maikrachline2020nuclearp38roles pages 14-16, schindler2007p38pathwaykinases pages 11-12).
8. Other Comments  
   A number of small-molecule inhibitors have been developed to target p38α due to its pivotal role in inflammatory signaling and various pathological conditions. Early inhibitors from the pyridinyl imidazole class, such as SB203580 and SB202190, competitively inhibit ATP binding to p38α and have been widely used in cellular and animal model studies. More recent inhibitors like BIRB0796 target p38α through alternative mechanisms that induce conformational changes independent of directly competing with ATP, thereby offering improved potency and isoform specificity. MAPK14 is associated with several disease states, including chronic inflammatory disorders, autoimmune conditions, cardiovascular diseases, and cancer, underscoring the therapeutic interest in modulating its activity. In addition to its kinase-dependent functions, emerging evidence suggests that p38α may also have kinase-independent roles mediated by protein–protein interactions that can affect functions such as protein O-GlcNAcylation and subcellular trafficking. These multifaceted roles of MAPK14 continue to drive research into its regulatory mechanisms and the development of more effective and selective inhibitors (lin2007novelstrategiesfor pages 1-2, marber2011thep38mitogenactivated pages 1-2, schindler2007p38pathwaykinases pages 5-6, yong2009thep38mapk pages 8-9).
9. References
10. cargnello2011activationandfunction pages 4-5
11. cuenda2007p38mapkinasespathway pages 1-2
12. cuenda2007p38mapkinasespathway pages 12-13
13. kyriakis2012mammalianmapksignal pages 3-5
14. lin2007novelstrategiesfor pages 1-2
15. maikrachline2020nuclearp38roles pages 14-16
16. marber2011thep38mitogenactivated pages 1-2
17. martinblanco2000p38mapksignalling pages 1-2
18. ono2000thep38signal pages 1-2
19. romerobecerra2020p38mapkpathway pages 1-3
20. schindler2007p38pathwaykinases pages 2-4
21. schindler2007p38pathwaykinases pages 5-6
22. yong2009thep38mapk pages 1-2
23. bradham2006p38mapkin pages 1-2
24. cuadrado2010mechanismsandfunctions pages 1-1
25. cuadrado2010mechanismsandfunctions pages 12-12
26. koul2013roleofp38 pages 2-4
27. kyriakis2001mammalianmitogenactivatedprotein pages 4-6
28. lin2007novelstrategiesfor pages 5-6
29. lin2007novelstrategiesfor pages 6-7
30. marber2011thep38mitogenactivated pages 5-6
31. marber2011thep38mitogenactivated pages 6-8
32. mittelstadt2005activatingp38mapk pages 5-5
33. ono2000thep38signal pages 8-9
34. raman2007differentialregulationand pages 6-7
35. raman2007differentialregulationand pages 7-8
36. roux2004erkandp38 pages 1-1
37. roux2004erkandp38 pages 2-3
38. schindler2007p38pathwaykinases pages 11-12
39. schindler2007p38pathwaykinases pages 13-13
40. schindler2007p38pathwaykinases pages 4-5
41. schindler2007p38pathwaykinases pages 6-7
42. yong2009thep38mapk pages 8-9
43. yong2009thep38mapk pages 9-10
44. canovas2021diversityandversatility pages 1-3

References

1. (cargnello2011activationandfunction pages 4-5): Marie Cargnello and Philippe P. Roux. Activation and function of the mapks and their substrates, the mapk-activated protein kinases. Microbiology and Molecular Biology Reviews, 75:50-83, Mar 2011. URL: https://doi.org/10.1128/mmbr.00031-10, doi:10.1128/mmbr.00031-10. This article has 3987 citations and is from a domain leading peer-reviewed journal.
2. (cuenda2007p38mapkinasespathway pages 1-2): Ana Cuenda and Simon Rousseau. P38 map-kinases pathway regulation, function and role in human diseases. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1773:1358-1375, Aug 2007. URL: https://doi.org/10.1016/j.bbamcr.2007.03.010, doi:10.1016/j.bbamcr.2007.03.010. This article has 1870 citations.
3. (cuenda2007p38mapkinasespathway pages 12-13): Ana Cuenda and Simon Rousseau. P38 map-kinases pathway regulation, function and role in human diseases. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1773:1358-1375, Aug 2007. URL: https://doi.org/10.1016/j.bbamcr.2007.03.010, doi:10.1016/j.bbamcr.2007.03.010. This article has 1870 citations.
4. (kyriakis2012mammalianmapksignal pages 3-5): John M. Kyriakis and Joseph Avruch. Mammalian mapk signal transduction pathways activated by stress and inflammation: a 10-year update. Physiological Reviews, 92:689-737, Apr 2012. URL: https://doi.org/10.1152/physrev.00028.2011, doi:10.1152/physrev.00028.2011. This article has 1591 citations and is from a highest quality peer-reviewed journal.
5. (lin2007novelstrategiesfor pages 1-2): A Lin J Zhang, B Shen. Novel strategies for inhibition of the p38 mapk pathway. Trends in Pharmacological Sciences, 28:286-295, Jun 2007. URL: https://doi.org/10.1016/j.tips.2007.04.008, doi:10.1016/j.tips.2007.04.008. This article has 210 citations and is from a highest quality peer-reviewed journal.
6. (maikrachline2020nuclearp38roles pages 14-16): Galia Maik-Rachline, Lucia Lifshits, and Rony Seger. Nuclear p38: roles in physiological and pathological processes and regulation of nuclear translocation. International Journal of Molecular Sciences, 21:6102, Aug 2020. URL: https://doi.org/10.3390/ijms21176102, doi:10.3390/ijms21176102. This article has 65 citations and is from a peer-reviewed journal.
7. (marber2011thep38mitogenactivated pages 1-2): Michael S. Marber, Beth Rose, and Yibin Wang. The p38 mitogen-activated protein kinase pathway—a potential target for intervention in infarction, hypertrophy, and heart failure. Journal of Molecular and Cellular Cardiology, 51:485-490, Oct 2011. URL: https://doi.org/10.1016/j.yjmcc.2010.10.021, doi:10.1016/j.yjmcc.2010.10.021. This article has 189 citations and is from a domain leading peer-reviewed journal.
8. (martinblanco2000p38mapksignalling pages 1-2): Enrique Martín-Blanco. P38 mapk signalling cascades: ancient roles and new functions. BioEssays, Jul 2000. URL: https://doi.org/10.1002/1521-1878(200007)22:7<637::aid-bies6>3.0.co;2-e, doi:10.1002/1521-1878(200007)22:7<637::aid-bies6>3.0.co;2-e. This article has 283 citations and is from a peer-reviewed journal.
9. (ono2000thep38signal pages 1-2): Koh Ono and Jiahuai Han. The p38 signal transduction pathway activation and function. Cellular Signalling, 12:1-13, Jan 2000. URL: https://doi.org/10.1016/s0898-6568(99)00071-6, doi:10.1016/s0898-6568(99)00071-6. This article has 2250 citations and is from a peer-reviewed journal.
10. (romerobecerra2020p38mapkpathway pages 1-3): Rafael Romero-Becerra, Ayelén Santamans, Cintia Folgueira, and Guadalupe Sabio. P38 mapk pathway in the heart: new insights in health and disease. International Journal of Molecular Sciences, 21:7412, Oct 2020. URL: https://doi.org/10.3390/ijms21197412, doi:10.3390/ijms21197412. This article has 137 citations and is from a peer-reviewed journal.
11. (schindler2007p38pathwaykinases pages 2-4): J.F. Schindler, J.B. Monahan, and W.G. Smith. P38 pathway kinases as anti-inflammatory drug targets. Journal of Dental Research, 86:800-811, Sep 2007. URL: https://doi.org/10.1177/154405910708600902, doi:10.1177/154405910708600902. This article has 331 citations and is from a highest quality peer-reviewed journal.
12. (schindler2007p38pathwaykinases pages 5-6): J.F. Schindler, J.B. Monahan, and W.G. Smith. P38 pathway kinases as anti-inflammatory drug targets. Journal of Dental Research, 86:800-811, Sep 2007. URL: https://doi.org/10.1177/154405910708600902, doi:10.1177/154405910708600902. This article has 331 citations and is from a highest quality peer-reviewed journal.
13. (yong2009thep38mapk pages 1-2): Hae-Young Yong, Min-Soo Koh, and Aree Moon. The p38 mapk inhibitors for the treatment of inflammatory diseases and cancer. Expert Opinion on Investigational Drugs, 18:1893-1905, Nov 2009. URL: https://doi.org/10.1517/13543780903321490, doi:10.1517/13543780903321490. This article has 419 citations and is from a peer-reviewed journal.
14. (bradham2006p38mapkin pages 1-2): Cynthia Bradham and David R. McClay. P38 mapk in development and cancer. Cell Cycle, 5:824-828, Apr 2006. URL: https://doi.org/10.4161/cc.5.8.2685, doi:10.4161/cc.5.8.2685. This article has 286 citations and is from a peer-reviewed journal.
15. (cuadrado2010mechanismsandfunctions pages 1-1): Ana Cuadrado and Angel R. Nebreda. Mechanisms and functions of p38 mapk signalling. The Biochemical journal, 429 3:403-17, Aug 2010. URL: https://doi.org/10.1042/bj20100323, doi:10.1042/bj20100323. This article has 2098 citations.
16. (koul2013roleofp38 pages 2-4): H. Koul, Mantu Pal, and S. Koul. Role of p38 map kinase signal transduction in solid tumors. Genes & Cancer, 4:342-359, Sep 2013. URL: https://doi.org/10.1177/1947601913507951, doi:10.1177/1947601913507951. This article has 588 citations.
17. (kyriakis2001mammalianmitogenactivatedprotein pages 4-6): John M. Kyriakis and Joseph Avruch. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiological Reviews, 81:807-869, Apr 2001. URL: https://doi.org/10.1152/physrev.2001.81.2.807, doi:10.1152/physrev.2001.81.2.807. This article has 4483 citations and is from a highest quality peer-reviewed journal.
18. (lin2007novelstrategiesfor pages 5-6): A Lin J Zhang, B Shen. Novel strategies for inhibition of the p38 mapk pathway. Trends in Pharmacological Sciences, 28:286-295, Jun 2007. URL: https://doi.org/10.1016/j.tips.2007.04.008, doi:10.1016/j.tips.2007.04.008. This article has 210 citations and is from a highest quality peer-reviewed journal.
19. (lin2007novelstrategiesfor pages 6-7): A Lin J Zhang, B Shen. Novel strategies for inhibition of the p38 mapk pathway. Trends in Pharmacological Sciences, 28:286-295, Jun 2007. URL: https://doi.org/10.1016/j.tips.2007.04.008, doi:10.1016/j.tips.2007.04.008. This article has 210 citations and is from a highest quality peer-reviewed journal.
20. (marber2011thep38mitogenactivated pages 5-6): Michael S. Marber, Beth Rose, and Yibin Wang. The p38 mitogen-activated protein kinase pathway—a potential target for intervention in infarction, hypertrophy, and heart failure. Journal of Molecular and Cellular Cardiology, 51:485-490, Oct 2011. URL: https://doi.org/10.1016/j.yjmcc.2010.10.021, doi:10.1016/j.yjmcc.2010.10.021. This article has 189 citations and is from a domain leading peer-reviewed journal.
21. (marber2011thep38mitogenactivated pages 6-8): Michael S. Marber, Beth Rose, and Yibin Wang. The p38 mitogen-activated protein kinase pathway—a potential target for intervention in infarction, hypertrophy, and heart failure. Journal of Molecular and Cellular Cardiology, 51:485-490, Oct 2011. URL: https://doi.org/10.1016/j.yjmcc.2010.10.021, doi:10.1016/j.yjmcc.2010.10.021. This article has 189 citations and is from a domain leading peer-reviewed journal.
22. (mittelstadt2005activatingp38mapk pages 5-5): Paul R. Mittelstadt, Jesús M. Salvador, Jr. Albert J. Fornace, and Jonathan D. Ashwell. Activating p38 mapk: new tricks for an old kinase. Cell Cycle, 4:1189-1192, Jul 2005. URL: https://doi.org/10.4161/cc.4.9.2043, doi:10.4161/cc.4.9.2043. This article has 137 citations and is from a peer-reviewed journal.
23. (ono2000thep38signal pages 8-9): Koh Ono and Jiahuai Han. The p38 signal transduction pathway activation and function. Cellular Signalling, 12:1-13, Jan 2000. URL: https://doi.org/10.1016/s0898-6568(99)00071-6, doi:10.1016/s0898-6568(99)00071-6. This article has 2250 citations and is from a peer-reviewed journal.
24. (raman2007differentialregulationand pages 6-7): Malavika Raman, Wei Chen, and M. Cobb. Differential regulation and properties of mapks. Oncogene, 26:3100-3112, May 2007. URL: https://doi.org/10.1038/sj.onc.1210392, doi:10.1038/sj.onc.1210392. This article has 1953 citations and is from a domain leading peer-reviewed journal.
25. (raman2007differentialregulationand pages 7-8): Malavika Raman, Wei Chen, and M. Cobb. Differential regulation and properties of mapks. Oncogene, 26:3100-3112, May 2007. URL: https://doi.org/10.1038/sj.onc.1210392, doi:10.1038/sj.onc.1210392. This article has 1953 citations and is from a domain leading peer-reviewed journal.
26. (roux2004erkandp38 pages 1-1): Philippe P. Roux and John Blenis. Erk and p38 mapk-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiology and Molecular Biology Reviews, 68:320-344, Jun 2004. URL: https://doi.org/10.1128/mmbr.68.2.320-344.2004, doi:10.1128/mmbr.68.2.320-344.2004. This article has 3345 citations and is from a domain leading peer-reviewed journal.
27. (roux2004erkandp38 pages 2-3): Philippe P. Roux and John Blenis. Erk and p38 mapk-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiology and Molecular Biology Reviews, 68:320-344, Jun 2004. URL: https://doi.org/10.1128/mmbr.68.2.320-344.2004, doi:10.1128/mmbr.68.2.320-344.2004. This article has 3345 citations and is from a domain leading peer-reviewed journal.
28. (schindler2007p38pathwaykinases pages 11-12): J.F. Schindler, J.B. Monahan, and W.G. Smith. P38 pathway kinases as anti-inflammatory drug targets. Journal of Dental Research, 86:800-811, Sep 2007. URL: https://doi.org/10.1177/154405910708600902, doi:10.1177/154405910708600902. This article has 331 citations and is from a highest quality peer-reviewed journal.
29. (schindler2007p38pathwaykinases pages 13-13): J.F. Schindler, J.B. Monahan, and W.G. Smith. P38 pathway kinases as anti-inflammatory drug targets. Journal of Dental Research, 86:800-811, Sep 2007. URL: https://doi.org/10.1177/154405910708600902, doi:10.1177/154405910708600902. This article has 331 citations and is from a highest quality peer-reviewed journal.
30. (schindler2007p38pathwaykinases pages 4-5): J.F. Schindler, J.B. Monahan, and W.G. Smith. P38 pathway kinases as anti-inflammatory drug targets. Journal of Dental Research, 86:800-811, Sep 2007. URL: https://doi.org/10.1177/154405910708600902, doi:10.1177/154405910708600902. This article has 331 citations and is from a highest quality peer-reviewed journal.
31. (schindler2007p38pathwaykinases pages 6-7): J.F. Schindler, J.B. Monahan, and W.G. Smith. P38 pathway kinases as anti-inflammatory drug targets. Journal of Dental Research, 86:800-811, Sep 2007. URL: https://doi.org/10.1177/154405910708600902, doi:10.1177/154405910708600902. This article has 331 citations and is from a highest quality peer-reviewed journal.
32. (yong2009thep38mapk pages 8-9): Hae-Young Yong, Min-Soo Koh, and Aree Moon. The p38 mapk inhibitors for the treatment of inflammatory diseases and cancer. Expert Opinion on Investigational Drugs, 18:1893-1905, Nov 2009. URL: https://doi.org/10.1517/13543780903321490, doi:10.1517/13543780903321490. This article has 419 citations and is from a peer-reviewed journal.
33. (yong2009thep38mapk pages 9-10): Hae-Young Yong, Min-Soo Koh, and Aree Moon. The p38 mapk inhibitors for the treatment of inflammatory diseases and cancer. Expert Opinion on Investigational Drugs, 18:1893-1905, Nov 2009. URL: https://doi.org/10.1517/13543780903321490, doi:10.1517/13543780903321490. This article has 419 citations and is from a peer-reviewed journal.
34. (canovas2021diversityandversatility pages 1-3): Begoña Canovas and Angel R. Nebreda. Diversity and versatility of p38 kinase signalling in health and disease. Nature Reviews Molecular Cell Biology, 22:346-366, Jan 2021. URL: https://doi.org/10.1038/s41580-020-00322-w, doi:10.1038/s41580-020-00322-w. This article has 499 citations and is from a domain leading peer-reviewed journal.
35. (cuadrado2010mechanismsandfunctions pages 12-12): Ana Cuadrado and Angel R. Nebreda. Mechanisms and functions of p38 mapk signalling. The Biochemical journal, 429 3:403-17, Aug 2010. URL: https://doi.org/10.1042/bj20100323, doi:10.1042/bj20100323. This article has 2098 citations.